Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP755977.RAONs1keuO9nzZW0iFxOVXhuWj32N9-8cucVsLbMlPZ80130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP755977.RAONs1keuO9nzZW0iFxOVXhuWj32N9-8cucVsLbMlPZ80130_assertion type Assertion NP755977.RAONs1keuO9nzZW0iFxOVXhuWj32N9-8cucVsLbMlPZ80130_head.
- NP755977.RAONs1keuO9nzZW0iFxOVXhuWj32N9-8cucVsLbMlPZ80130_assertion description "[This multicentre phase II study investigated the efficacy and toxicity of the HER2 antibody trastuzumab combined with capecitabine in the patients with pancreatic cancer and HER2 overexpression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP755977.RAONs1keuO9nzZW0iFxOVXhuWj32N9-8cucVsLbMlPZ80130_provenance.
- NP755977.RAONs1keuO9nzZW0iFxOVXhuWj32N9-8cucVsLbMlPZ80130_assertion evidence source_evidence_literature NP755977.RAONs1keuO9nzZW0iFxOVXhuWj32N9-8cucVsLbMlPZ80130_provenance.
- NP755977.RAONs1keuO9nzZW0iFxOVXhuWj32N9-8cucVsLbMlPZ80130_assertion SIO_000772 22374460 NP755977.RAONs1keuO9nzZW0iFxOVXhuWj32N9-8cucVsLbMlPZ80130_provenance.
- NP755977.RAONs1keuO9nzZW0iFxOVXhuWj32N9-8cucVsLbMlPZ80130_assertion wasDerivedFrom befree-20140225 NP755977.RAONs1keuO9nzZW0iFxOVXhuWj32N9-8cucVsLbMlPZ80130_provenance.
- NP755977.RAONs1keuO9nzZW0iFxOVXhuWj32N9-8cucVsLbMlPZ80130_assertion wasGeneratedBy ECO_0000203 NP755977.RAONs1keuO9nzZW0iFxOVXhuWj32N9-8cucVsLbMlPZ80130_provenance.